Kiniksa Pharmaceuticals Ltd (KNSA)vsMerck & Company Inc (MRK)
KNSA
Kiniksa Pharmaceuticals Ltd
$52.99
-1.60%
HEALTHCARE · Cap: $4.08B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 9495% more annual revenue ($65.01B vs $677.56M). MRK leads profitability with a 28.1% profit margin vs 8.7%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
KNSA
Buy51
out of 100
Grade: C-
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$202.90
Current Price
$52.99
$149.91 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Earnings expanding 550.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 58.2x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 51/100), backed by strong 28.1% margins. KNSA offers better value entry with a 77.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?